.Pharmacolibrary.Drugs.ATC.A.A10AD04 .Pharmacolibrary.Drugs.ATC.A.A10AD04| name: | InsulinLispro |
| ATC code: | A10AD04 | route: | subcutaneous |
| n-compartments | 1 |
Insulin lispro is a rapid-acting human insulin analog used to improve glycemic control in patients with diabetes mellitus. It is approved for use in both type 1 and type 2 diabetes and is typically administered by subcutaneous injection before meals.
Reported values for healthy adult subjects with type 1 diabetes following subcutaneous injection.
de la Peña, A, et al., & Ignaut, DA (2015). Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects. Journal of diabetes science and technology 9(4) 824–830. DOI:10.1177/1932296815573865 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25697717
Chao, M, et al., & Ning, G (2010). Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro. Endocrine 38(1) 48–52. DOI:10.1007/s12020-010-9326-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20960101
Shiramoto, M, et al., & Ohwaki, K (2020). Ultra-Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog. Journal of diabetes investigation 11(3) 672–680. DOI:10.1111/jdi.13195 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31816193